Bafna Pharmaceuticals Ltd (BAFP)

Currency in INR
85.39
+4.01(+4.93%)
Closed·

BAFP Financial Summary

Key Ratios

P/E Ratio48.52
Price/Book2.12
Debt / Equity33.25%
Return on Equity5.01%
Dividend Yield0.00%
EBITDA111.77M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Earnings

Latest Release
May 26, 2025
EPS / Forecast
0.55 / --
Revenue / Forecast
400.85M / --
EPS Revisions
Last 90 days

FAQ

What were Bafna Pharmaceuticals's earnings for the latest quarter?

The Bafna Pharmaceuticals EPS (TTM) is 1.76. Bafna Pharmaceuticals reported sales of 390.60, net income of 13.11, and EPS of 0.55 for the latest quarter.

What was Bafna Pharmaceuticals's net income for the latest quarter?

Bafna Pharmaceuticals's net income for the latest quarter was 13.11.

How did Bafna Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 331.88 in the previous quarter to 390.60 in the latest quarter, and net income moved from 9.48 to 13.11 compared to the previous quarter.

What is Bafna Pharmaceuticals's net profit margin on a TTM basis?

Bafna Pharmaceuticals's trailing twelve months (TTM) net profit margin is 2.85%.

How does Bafna Pharmaceuticals's debt to equity ratio compare to industry standards?

Bafna Pharmaceuticals's total debt-to-equity ratio is 33.25%.

What is Bafna Pharmaceuticals's return on investment on a TTM basis?

Bafna Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 5.01%.

What were Bafna Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Bafna Pharmaceuticals reported total assets of 1,530.79 million and total liabilities of 518.52 million.

How has Bafna Pharmaceuticals's total revenue grown this year?

Bafna Pharmaceuticals's total revenue was 331.88 in the previous quarter and 390.60 in the latest quarter.

What is Bafna Pharmaceuticals's gross margin on a TTM basis?

Bafna Pharmaceuticals's trailing twelve months (TTM) gross margin is 29.34%.

What was Bafna Pharmaceuticals's revenue per share for the latest quarter?

Bafna Pharmaceuticals's revenue per share for the latest quarter was 301.64.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.